洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
机构信息
Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.
The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China.
出版信息
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
Abstract
In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.
摘要
在过去的几十年中，冠状病毒已成为全球公共卫生的威胁。目前，武汉爆发的新型冠状病毒病（COVID-19）引起了全球恐慌。目前尚无针对 COVID-19 的特效抗病毒疗法。但是，在严重急性呼吸综合征（SARS）和中东呼吸综合征（MERS）流行期间使用过一些药物。我们可以从 SARS 和 MERS 中吸取经验。洛匹那韦（LPV）是一种有效的抑制剂，可抑制冠状病毒的蛋白酶活性。在这篇综述中，我们讨论了 LPV 在体外和体内的功效的文献，特别是在 SARS 和 MERS 患者中的应用，以期阐明 LPV 在 COVID-19 患者中的应用潜力。
相似文献
1
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
2
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.严重急性呼吸综合征（SARS）、中东呼吸综合征（MERS）和严重急性呼吸综合征冠状病毒 2（COVID-19）治疗：专利述评。
Expert Opin Ther Pat. 2020 Aug;30(8):567-579. doi: 10.1080/13543776.2020.1772231. Epub 2020 Jun 7.
3
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.具有治疗新型呼吸道 2019 冠状病毒潜力的化合物。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00399-20.
4
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.洛匹那韦/利托那韦治疗严重急性呼吸综合征、中东呼吸综合征和 COVID-19：系统评价。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659.
5
Overview of lethal human coronaviruses.致死性人类冠状病毒概述。
Signal Transduct Target Ther. 2020 Jun 10;5(1):89. doi: 10.1038/s41392-020-0190-2.
6
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
7
A global treatments for coronaviruses including COVID-19.全球针对冠状病毒（包括 COVID-19）的治疗方法。
J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11.
8
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.用恢复期血浆治疗 COVID-19：从过去的冠状病毒爆发中吸取的教训。
Clin Microbiol Infect. 2020 Oct;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005. Epub 2020 Aug 11.
9
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.抗 SARS、MERS 或 COVID-19 病毒的抗逆转录病毒药物的疗效和安全性的系统评价：初步评估。
J Int AIDS Soc. 2020 Apr;23(4):e25489. doi: 10.1002/jia2.25489.
10
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防：回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
引用本文的文献
1
A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.2019年新型冠状病毒病疫苗接种、诊断与治疗中的主要挑战简明综述
Arch Razi Inst. 2024 Dec 31;79(6):1155-1164. doi: 10.32592/ARI.2024.79.6.1155. eCollection 2024 Dec.
2
Treatment and Outcomes of COVID-19 Infection in Pregnant Women: Systematic Review of Cases Reported in Europe.孕妇新冠病毒感染的治疗与结局：欧洲报告病例的系统评价
J Clin Med. 2025 May 27;14(11):3743. doi: 10.3390/jcm14113743.
3
Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.潜在的广谱抗病毒药物：对抗新出现和再次出现的呼吸道RNA病毒的关键武器库。
Int J Mol Sci. 2025 Feb 10;26(4):1481. doi: 10.3390/ijms26041481.
4
ACVPICPred: Inhibitory activity prediction of anti-coronavirus peptides based on artificial neural network.ACVPICPred：基于人工神经网络的抗冠状病毒肽抑制活性预测
Comput Struct Biotechnol J. 2024 Oct 2;23:3625-3633. doi: 10.1016/j.csbj.2024.09.015. eCollection 2024 Dec.
5
The Ethical Obligation for Research During Public Health Emergencies: Insights From the COVID-19 Pandemic.突发公共卫生事件中的研究伦理义务：COVID-19 大流行带来的启示。
Med Health Care Philos. 2024 Mar;27(1):49-70. doi: 10.1007/s11019-023-10184-6. Epub 2023 Dec 28.
6
Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses.新冠病毒洞察：药物疗法与宿主细胞反应之观点。
Biomolecules. 2023 Sep 26;13(10):1452. doi: 10.3390/biom13101452.
7
Hospital response challenges and strategies during COVID-19 pandemic: a qualitative study.医院应对 COVID-19 大流行的挑战和策略：一项定性研究。
Front Public Health. 2023 Jun 30;11:1167411. doi: 10.3389/fpubh.2023.1167411. eCollection 2023.
8
e-Pharmacophore modeling and in silico study of CD147 receptor against SARS-CoV-2 drugs.针对SARS-CoV-2药物的CD147受体的电子药效团建模与计算机模拟研究
Genomics Inform. 2023 Jun;21(2):e17. doi: 10.5808/gi.23005. Epub 2023 Jun 30.
9
Broad-Spectrum Antivirals against Multiple Human and Animal Coronaviruses Infection.针对多种人类和动物冠状病毒感染的广谱抗病毒药物。
Pathogens. 2023 Jun 11;12(6):823. doi: 10.3390/pathogens12060823.
10
[Not Available].[无可用内容]。
Adv Lab Med. 2020 Sep 3;1(4):20200045. doi: 10.1515/almed-2020-0045. eCollection 2020 Dec.
本文引用的文献
1
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.四例新型冠状病毒肺炎患者采用中西医结合治疗的临床特点和治疗经过。
Biosci Trends. 2020 Mar 16;14(1):64-68. doi: 10.5582/bst.2020.01030. Epub 2020 Feb 9.
2
[Potential antiviral therapeutics for 2019 Novel Coronavirus].[2019新型冠状病毒的潜在抗病毒治疗方法]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 5;43(0):E002. doi: 10.3760/cma.j.issn.1001-0939.2020.0002.
3
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
4
Drug treatment options for the 2019-new coronavirus (2019-nCoV).针对 2019 新型冠状病毒（2019-nCoV）的药物治疗选择。
Biosci Trends. 2020 Mar 16;14(1):69-71. doi: 10.5582/bst.2020.01020. Epub 2020 Jan 28.
5
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.比较瑞德西韦与洛匹那韦利托那韦和干扰素β联合治疗中东呼吸综合征冠状病毒的疗效。
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
6
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.中东呼吸综合征的洛匹那韦/利托那韦联合干扰素-β1b 治疗（MIRACLE 试验）：递归两阶段分组序贯随机对照试验的统计分析计划。
Trials. 2020 Jan 3;21(1):8. doi: 10.1186/s13063-019-3846-x.
7
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.医护人员中东呼吸综合征感染后的预防措施。
J Hosp Infect. 2019 Jan;101(1):42-46. doi: 10.1016/j.jhin.2018.09.005. Epub 2018 Sep 18.
8
Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.洛匹那韦/利托那韦、利巴韦林和α干扰素联合治疗中东呼吸综合征
Antivir Ther. 2016;21(5):455-9. doi: 10.3851/IMP3002. Epub 2015 Oct 22.
9
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome.中东呼吸综合征抗病毒治疗指南
Infect Chemother. 2015 Sep;47(3):212-22. doi: 10.3947/ic.2015.47.3.212. Epub 2015 Sep 30.
10
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.洛匹那韦/利托那韦或干扰素-β1b治疗可改善普通狨猴中东呼吸综合征冠状病毒感染非人灵长类动物模型的预后。
J Infect Dis. 2015 Dec 15;212(12):1904-13. doi: 10.1093/infdis/jiv392. Epub 2015 Jul 21.
Zotero 插件